摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

茜素双酯 UV | 59883-07-7

中文名称
茜素双酯 UV
中文别名
二乙基1,4-二羟基萘-2,3-二羧酸;茜素双酯UV;茜草双酯
英文名称
Diethyl 1,4-dihydroxynaphthalene-2,3-dicarboxylate
英文别名
1,4-dihydroxy-naphthalene-2,3-dicarboxylic acid diethyl ester;1,4-Dihydroxy-naphthalin-2,3-dicarbonsaeure-diaethylester;ethyl 1,4-dihydroxy-2,3-naphthalenedicarboxylate;diethyl 1,4-dihydroxy-2,3-naphthalenedicarboxylate
茜素双酯 UV化学式
CAS
59883-07-7
化学式
C16H16O6
mdl
——
分子量
304.299
InChiKey
GTBYFJITPRWOBT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4
  • 重原子数:
    22
  • 可旋转键数:
    6
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    93.1
  • 氢给体数:
    2
  • 氢受体数:
    6

安全信息

  • 海关编码:
    2918290000
  • 危险性防范说明:
    P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P362,P403+P233,P501
  • 危险性描述:
    H315,H319,H335
  • 储存条件:
    室温密封保存,并保持干燥。

SDS

SDS:7385341f2d9808cf203c16ecd78b6156
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS FOR THE TREATMENT OF PAIN<br/>[FR] COMPOSÉS ORIGINAUX
    申请人:GLAXO GROUP LTD
    公开号:WO2009019281A1
    公开(公告)日:2009-02-12
    A compound of formula (I) wherein R1 represents C1-4alkyl or C1-4alkoxy; R2 represents C1-4alkyl or C1-4alkenyl; R3 represents H, F, Cl, methyl, methoxy or CF3; R4 represents H or F; X represents CH2 or C=O; and Y represents CH2 or C=O, provided that at least one of X and Y represents C=O and at least one of R3 and R4 is H; and pharmaceutically acceptable derivatives thereof, processes for preparing such compounds, a pharmaceutical composition comprising such compounds and the use of such compounds in medicine.
    化合物的化学式(I),其中R1代表C1-4烷基或C1-4烷氧基;R2代表C1-4烷基或C1-4烯基;R3代表H、F、Cl、甲基、甲氧基或CF3;R4代表H或F;X代表CH2或C=O;Y代表 或C=O,前提是至少一个X和Y代表C=O,至少一个R3和R4代表H;及其药用可接受衍生物,制备这种化合物的方法,包含这种化合物的药物组合物以及这种化合物在医学中的用途。
  • N-Heterocyclic carbene based catalytic platform for Hauser–Kraus annulations
    作者:Mohammed Sharique、Uttam K. Tambar
    DOI:10.1039/d0sc03116j
    日期:——
    annulation is an effective and convergent method for generating oxygenated polycyclic aromatic compounds. Despite its application in complex molecule synthesis, the harsh and strongly basic conditions can limit its utility in more functionalized molecular settings. We have developed the first catalytic Hauser–Kraus annulation based on N-heterocyclic carbene catalysis that proceeds under milder conditions
    古老的 Hauser-Kraus 环化是生成含氧多环芳族化合物的有效且收敛的方法。尽管它应用于复杂的分子合成,但苛刻和强碱性的条件会限制其在更多功能化的分子环境中的应用。我们开发了第一个基于 N-杂环卡宾催化的催化 Hauser-Kraus 环化,该催化在较温和的条件下进行。我们展示了在存在几个功能组的情况下的转换范围。我们还提出了一种通过非规范 Breslow 中间体进行的环化的协调机制。
  • Asymmetric synthesis of ternaphthalenes via an ester-mediated nucleophilic aromatic substitution reaction
    作者:Tetsutaro Hattori、Hiroaki Iwato、Koichi Natori、Sotaro Miyano
    DOI:10.1016/j.tetasy.2004.01.021
    日期:2004.3
    A convenient method is presented for the asymmetric synthesis of axially chiral 1,1′:5′,1″- and 1,1′:4′,1″-ternaphthalenes via the ester-mediated nucleophilic aromatic substitution reaction. Thus, treatment of dimenthyl 1,5-dimenthoxynaphthalene-2,6-dicarboxylate 7 and its regioisomer, dimenthyl 1,4-dimenthoxynaphthalene-2,3-dicarboxylate 10, with 2-methoxynaphthalen-1-ylmagnesium bromide 12 gave enantiomerically
    提出了一种方便的方法,通过酯介导的亲核芳香取代反应,不对称合成轴向手性的1,1':5',1''-和1,1':4',1''-。因此,治疗dimenthyl 1,5- dimenthoxynaphthalene吡啶-2,6-二羧酸的7和其部位异构体,dimenthyl 1,4- dimenthoxynaphthalene -2,3-二羧酸酯10,用2-甲氧基-1- ylmagnesium化物12,得到对映异构体和非对映体纯二薄荷基2,2''-二甲氧基-1,1':5',1''-2',6'-二羧酸3和二薄荷基2,2''-二甲氧基-1,1':4',1''-色谱纯化后,-2',3'-二羧酸4的收率分别为70%和63%。
  • An efficient synthesis of p-quinones utilizing a novel Pummerer-type rearrangement of p-sulfinylphenols
    作者:Shuji Akai、Yoshifumi Takeda、Kiyosei Iio、Yutaka Yoshida、Yasuyuki Kita
    DOI:10.1039/c39950001013
    日期:——
    Treatment of the p-sulfinylphenol derivatives 1 and 5 with trifluoroacetic anhydride causes a Pummerer-type rearrangement on aromatic rings and concomitant desulfurization to give 1 : 1 mixtures of the corresponding p-quinones and p-dihydroquinones, which are subjected to mild oxidation to provide high yields of p-quinones 3 and 7.
    对亚磺酰基苯酚生物 1 和 5 经三氟乙酸酐处理后,会在芳香环上发生普默尔型重排反应,同时发生脱反应,从而得到 1 : 1 的相应对醌和对二氢醌混合物。
  • Analgesic basic naphthalene derivatives
    申请人:Glaxo Laboratories Limited
    公开号:US04062955A1
    公开(公告)日:1977-12-13
    Compounds of the general formula: ##STR1## wherein the groups CHR.sup.1 NR.sup.2 R.sup.3 and CHR.sup.4 NR.sup.5 R.sup.6 may be the same or different and where the group CHR.sup.4 NR.sup.5 R.sup.6 is in either the 1 or the 3 position and R.sup.1 and R.sup.4 independently represent a hydrogen atom or an aryl group; R.sup.2, r.sup.3, r.sup.5 and R.sup.6 which may be the same or different are each a hydrogen atom or an alkyl group or an aryl group both of which may in turn be substituted by one or more hydroxy, alkoxy, acyloxy, dialkylamino or aryl groups or the groups --NR.sup.2 R.sup.3 and/or NR.sup.5 R.sup.6 represent a heterocyclic ring containing one or more hetero atoms and which ring may optionally be substituted by an alkyl, aryl or aralkyl group and in which either aromatic ring of the naphthalene nucleus may be further substituted; with the proviso that when R.sup.1, R.sup.4, R.sup.2 and R.sup.5 are hydrogen, then R.sup.3 and R.sup.6 cannot both be benzyl, when the second substituent is in the 1 position; and when R.sup.1 and R.sup.4 are hydrogen, then R.sup.2, R.sup.3, R.sup.5 and R.sup.6 cannot all be methyl when the second substituent is in the 1 position; and when R.sup.1 and R.sup.4 are hydrogen, then R.sup.2 and R.sup.3 and R.sup.5 and R.sup.6 together with the nitrogen atom cannot both be piperidino when the second substituent is in the 3 position and the naphthalene nucleus is further substituted by hydroxy in the 1 and 4 positions; and pharmaceutically acceptable salts of such compounds; and hydrates of such compounds and such salts. The compounds have activity on the central nervous system in particular as analgesics.
    通式为## STR1 ##的化合物,其中CHR.sup.1 NR.sup.2 R.sup.3和CHR.sup.4 NR.sup.5 R.sup.6基团可以相同也可以不同,且CHR.sup.4 NR.sup.5 R.sup.6基团位于1或3位置,R.sup.1和R.sup.4分别代表氢原子或芳基基团; R.sup.2,r.sup.3,r.sup.5和R.sup.6可以相同也可以不同,分别是氢原子或烷基或芳基基团,这些基团又可以被一个或多个羟基,烷氧基,酰氧基,二烷基基或芳基基团所取代,或者--NR.sup.2 R.sup.3和/或NR.sup.5 R.sup.6代表含有一个或多个杂原子的杂环,该环可以被烷基,芳基或芳基烷基所取代,并且核的任一芳环可以进一步取代; 前提是当R.sup.1,R.sup.4,R.sup.2和R.sup.5为氢时,当第二取代基位于1位置时,R.sup.3和R.sup.6不能同时为苄基; 当R.sup.1和R.sup.4为氢时,当第二取代基位于1位置时,R.sup.2,R.sup.3,R.sup.5和R.sup.6不能都为甲基; 当R.sup.1和R.sup.4为氢时,当第二取代基位于3位置且核在1和4位置进一步取代为羟基时,R.sup.2和R.sup.3和R.sup.5和R.sup.6连同氮原子不能同时为哌啶基; 这些化合物的药学上可接受的盐以及这些化合物和这些盐的合物具有中枢神经系统活性,特别是作为镇痛剂。
查看更多